Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV-B® to Licensed Vaccine (Engerix-B®) Among Adults(18 to 75 Years of Age) With Chronic Kidney Disease (CKD)

NCT00985426 is registered in ClinicalTrials.gov with Dynavax Technologies Corporation as lead sponsor.

NCT NCT00985426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00985426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV-B® to Licensed Vaccine (Engerix-B®) Among Adults(18 to 75 Years of Age) With Chronic Kidney Disease (CKD)
Lead sponsor
Dynavax Technologies Corporation
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2009
Completion date
January 31, 2012
Enrollment
521 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease